A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative

Abstract

ReuseThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ABSTRACT Background: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study

“…In recent years, the rheumatology community has witnessed an intense search for sensitive and valid instruments that capture those clinical aspects related to disease activity, as well as those linked to the response to the scheduled treatments, along with other instruments, more focused on the experiences and perceptions lived by PsA patients [3][4][5][6]15]. Despite this intense search, there is a remarkable mismatch between the results derived from the instruments for measuring disease activity (e.g., DAPSA), or those that assess the treatment objectives (e.g., MDA), and the PROMs (e.g., pain, fatigue, PsAID).…”

Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study

“…However, several of the tools have some evidence for good measurement properties in PsA (52). To optimize treatment strategies, clinicians and patients need insight into how pain mechanisms, disease activity, and sociodemographic and psychological factors interact and contribute to the overall prognosis.…”

“…Measurements of the COS domains were pragmatically chosen, since a recommended set of COS instruments is not yet endorsed by OMERACT. However, several of the tools have some evidence for good measurement properties in PsA (52).…”

Disease Features Associated with a low Disease Impact in Patients with Psoriatic Arthritis: Results of a Cross-Sectional Multicenter Study

“…Clinical remission characteristics of the study population are shown in Table 2 In recent years, the rheumatology community has witnessed an intense search for sensitive and valid instruments that capture those clinical aspects related to disease activity, as well as those linked to the response to the scheduled treatments; along with other instruments, more focused on the experiences and perceptions lived by PsA patients [3][4][5][6]15]. Despite this intense search, there is a remarkable mismatch between the results derived from the instruments for measuring disease activity (e.g., DAPSA), or those that assess the treatment objectives (e.g., MDA), and the PROMs (e.g., pain, fatigue, PsAID).…”